Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Kala Pharmaceuticals, Inc. develops pharmaceutical formulations. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. Kala Pharmaceuticals markets its products worldwide.
Website: kalarx.com


  • Bad financial results growth rate -25.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (14.6%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1 718.5% (LTM)
  • Share price is 11.8% higher than minimum and 97.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (0.3x vs 0.2x)

Key Financials (Download financials)

Ticker: KALA
Share price, USD:  (0.0%)0.6211
year average price 5.4362  


year start price 6.8100 2025-01-11

max close price 19.6300 2025-09-19

min close price 0.5556 2025-12-16

current price 0.6211 2026-01-10
Common stocks: 1 499 001

Dividend Yield:  0.0%
EV / Sales: -6.8x
Margin (EBITDA LTM / Revenue): -2 000.0%

Target EV / EBITDA (hist percentile): 0.2x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1
Net Debt ($m): -28
EV (Enterprise Value): -27
EBITDA LTM (млн $): -80
Price to Book: -0.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-08-13zacks.com

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

2024-12-30globenewswire.com

KALA BIO Announces $10,750,000 Private Placement

2024-12-16zacks.com

KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

2024-11-27globenewswire.com

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

2024-10-09zacks.com

KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade

2024-08-23zacks.com

KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

2024-04-04Zacks Investment Research

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?

2023-11-13Zacks Investment Research

KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-19 2025-08-08 2025-05-14 2024-11-12 2024-08-06 2024-05-14 2024-03-29 2023-11-13 2023-08-04 2023-05-09 2023-03-03 2022-11-08
acceptedDate 2025-11-19 07:26:53 2025-08-08 08:06:19 2025-05-14 16:22:15 2024-11-12 16:01:40 2024-08-06 16:01:40 2024-05-14 16:08:23 2024-03-29 08:06:07 2023-11-13 08:10:42 2023-08-04 08:08:14 2023-05-09 16:02:01 2023-03-03 08:16:06 2022-11-08 16:01:58
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0 70 000 0 0 0 1M 420 000
costOfRevenue 0 67 000 0 0 61 000 66 000 70 000 157 000 77 000 0 3M 11 000
grossProfit 0 -67 000 -68 000 0 -61 000 -66 000 0 -157 000 -77 000 0 -1M 409 000
grossProfitRatio 0 0 0 0 0 0 0 0 0 0 -1.085 0.974
researchAndDevelopmentExpenses 6M 6M 6M 5M 5M 6M 5M 6M 4M 4M 3M 5M
generalAndAdministrativeExpenses 5M 5M 5M 4M 4M 5M 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 -66 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 5M 4M 4M 5M 5M 5M 5M 6M 6M 10M
otherExpenses -3M 153 000 0 0 0 0 -5000 -2M -119 000 -2M -1M 0
operatingExpenses 7M 11M 11M 10M 10M 12M 9M 11M 9M 10M 9M 15M
costAndExpenses 7M 11M 11M 10M 10M 12M 9M 11M 9M 10M 9M 15M
interestIncome 270 000 407 000 463 000 570 000 504 000 504 000 610 000 708 000 718 000 675 000 354 000 234 000
interestExpense 963 000 1M 1M 1M 1M 1M 1M -1M 1M 1M 2M 1M
depreciationAndAmortization 128 000 67 000 68 000 63 000 61 000 66 000 43 812 79 000 77 000 319 000 82 000 828 000
ebitda -6M -10M -8M -7M -8M -12M -9M -9M -9M -11M -10M -14M
ebitdaratio 0 0 0 0 0 0 -132.443 0 0 0 -8.281 -32.626
operatingIncome -7M -11M -11M -10M -10M -12M -9M -9M -10M -12M -10M -15M
operatingIncomeRatio 0 0 0 0 0 0 -133.443 0 0 0 -8.348 -34.598
totalOtherIncomeExpensesNet -325 000 -127 000 2M 1M 26 000 -34 000 714 000 58 000 -478 000 -3M -3M 44M
incomeBeforeTax -8M -11M -9M -9M -10M -12M -9M -9M -10M -14M -13M 29M
incomeBeforeTaxRatio 0 0 0 0 0 0 -123.243 0 0 0 -10.458 69.221
incomeTaxExpense 0 0 0 0 0 22 724 -5M -79 000 1M 4M 1M -44M
netIncome -8M -11M -9M -9M -10M -12M -9M -9M -10M -19M -14M 73M
netIncomeRatio 0 0 0 0 0 0 -123.243 0 0 0 -11.287 174.874
eps -1.07 -1.71 -1.41 -1.93 -3.16 -4.2 -3.18 -3.41 -4.36 -9.04 -8.6 49
epsdiluted -1.07 -1.71 -1.41 -1.93 -3.16 -4.2 -3.18 -3.41 -4.36 -9.04 -8.6 48.63
weightedAverageShsOut 7M 7M 6M 5M 3M 3M 3M 3M 2M 2M 2M 1M
weightedAverageShsOutDil 7M 7M 6M 5M 3M 3M 3M 3M 2M 2M 2M 2M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-19 2025-08-08 2025-05-14 2024-11-12 2024-08-06 2024-05-14 2024-03-29 2023-11-13 2023-08-04 2023-05-09 2023-03-03 2022-11-08
acceptedDate 2025-11-19 07:26:53 2025-08-08 08:06:19 2025-05-14 16:22:15 2024-11-12 16:01:40 2024-08-06 16:01:40 2024-05-14 16:08:23 2024-03-29 08:06:07 2023-11-13 08:10:42 2023-08-04 08:08:14 2023-05-09 16:02:01 2023-03-03 08:16:06 2022-11-08 16:01:58
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 21M 32M 42M 49M 54M 48M 51M 56M 49M 64M 70M 52M
shortTermInvestments 0 0 0 0 0 0 100M 0 10M 0 0 0
cashAndShortTermInvestments 21M 32M 42M 49M 54M 48M 51M 56M 59M 64M 70M 52M
netReceivables 0 127 000 2M 0 3M 0 236 000 272 000 306 000 1M 6M 11M
inventory 0 0 0 0 0 0 0 0 5M 5M 8M 0
otherCurrentAssets 3M 2M 1M 2M 1M 2M 2M 2M 807 000 1M 1M 12M
totalCurrentAssets 24M 34M 46M 51M 59M 50M 53M 58M 66M 71M 86M 85M
propertyPlantEquipmentNet 603 000 2M 2M 3M 2M 3M 3M 3M 637 000 510 000 416 000 551 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 226 000 239 000 0 273 000 287 000 301 000 314 000 328 000 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 144 000 0 0 260 000 0 -1 0 0 0 372 000 462 000 475 000
totalNonCurrentAssets 747 000 2M 3M 3M 3M 3M 3M 3M 965 000 882 000 878 000 1M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0
totalAssets 25M 36M 48M 54M 62M 53M 56M 61M 67M 72M 87M 86M
accountPayables 917 000 658 000 931 000 711 000 665 000 732 000 919 000 787 000 760 000 997 000 3M 7M
shortTermDebt 29M 10M 16M 19M 13M 6M 334 000 324 000 -4M 3000 5M 32 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 546 000 314 000 2M 0 1M 3M 4M 4M 4M 3M
otherCurrentLiabilities 3M 5M 6M 4M 4M 5M 6M 6M 9M 5M 14M 29M
totalCurrentLiabilities 33M 16M 23M 24M 19M 12M 8M 10M 10M 10M 26M 40M
longTermDebt 1M 20M 16M 19M 24M 29M 34M 36M 34M 33M 38M 43M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 3M 3M 5M 4M 6M 6M 4M 6M 5M 4M 36M
totalNonCurrentLiabilities 1M 23M 20M 23M 29M 34M 40M 40M 39M 39M 42M 46M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 2M 2M 2M 2M 2M 2M 2M 0 3000 13 000 32 000
totalLiabilities 1M 39M 43M 47M 48M 46M 48M 50M 49M 49M 68M 87M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 7000 7000 6000 5000 5000 3000 3000 3000 3000 2000 2000 1000
retainedEarnings -696M -688M -677M -660M -651M -641M -629M -621M -612M -602M -587M -574M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 1000 9000 0 0 0
othertotalStockholdersEquity 687M 685M 683M 667M 665M 648M 637M 632M 630M 625M 606M 573M
totalStockholdersEquity -9M -3M 6M 7M 14M 7M 8M 11M 17M 23M 19M -968 000
totalEquity -9M -3M 6M 7M 14M 7M 8M 11M 17M 23M 19M -968 000
totalLiabilitiesAndStockholdersEquity 25M 36M 48M 54M 62M 53M 56M 61M 67M 72M 87M 86M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 25M 36M 48M 54M 62M 53M 56M 61M 67M 72M 87M 86M
totalInvestments 0 226 000 239 000 0 273 000 287 000 301 000 314 000 10M 0 0 0
totalDebt 30M 11M 32M 37M 37M 37M 36M 36M 34M 33M 43M 43M
netDebt 9M -21M -10M -12M -17M -12M -15M -20M -16M -30M -28M -10M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA KALA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-19 2025-08-08 2025-05-14 2024-11-12 2024-08-06 2024-05-14 2024-03-29 2023-11-13 2023-08-04 2023-05-09 2023-03-03 2022-11-08
acceptedDate 2025-11-19 07:26:53 2025-08-08 08:06:19 2025-05-14 16:22:15 2024-11-12 16:01:40 2024-08-06 16:01:40 2024-05-14 16:08:23 2024-03-29 08:06:07 2023-11-13 08:10:42 2023-08-04 08:08:14 2023-05-09 16:02:01 2023-03-03 08:16:06 2022-11-08 16:01:58
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -8M -11M -9M -9M -10M -12M -9M -9M -10M -14M -13M 29M
depreciationAndAmortization 128 000 67 000 68 000 63 000 61 000 66 000 70 000 79 000 77 000 77 000 80 000 151 000
deferredIncomeTax 0 0 0 0 0 0 -2M 0 0 0 0 0
stockBasedCompensation 2M 2M 2M 2M 2M 2M 2M 2M 1M 1M 960 000 1M
changeInWorkingCapital 2M 694 000 -3M 1M -2M -2M -2M 9M 758 000 1M -3M -2M
accountsReceivables 0 0 0 0 0 0 0 0 -2000 80 000 -5000 14M
inventory 0 0 0 0 0 0 -8M 5M 111 000 2M 3M 573 000
accountsPayables 259 000 -273 000 303 000 46 000 -67 000 -187 000 132 000 27 000 -237 000 -2M -5M -3M
otherWorkingCapital 2M 967 000 -3M 1M -2M -2M -2M 4M 886 000 -443 000 -2M -13M
otherNonCashItems -7M 420 000 297 000 839 000 468 000 3M 3M -6M 621 000 2M 1M -44M
netCashProvidedByOperatingActivities -11M -8M -9M -5M -9M -11M -8M -3M -8M -10M -14M -16M
investmentsInPropertyPlantAndEquipment 16 000 -16 000 0 49 000 -36 000 -13 000 -7000 -281 000 -214 000 -108 000 -22 000 -38 000
acquisitionsNet 0 0 0 0 0 0 -47 000 0 47 000 0 -63M 63M
purchasesOfInvestments 0 0 0 0 0 0 0 0 -10M 0 10M -5M
salesMaturitiesOfInvestments 0 0 0 0 0 0 47 000 10M -47 000 0 -5M 2M
otherInvestingActivites -15 000 0 0 -139 000 0 -13 000 -610 000 0 47 000 0 58M 5M
netCashUsedForInvestingActivites 1000 -16 000 0 -90 000 -36 000 -13 000 -7000 10M -10M -108 000 51 000 65M
debtRepayment 0 -3M -28 000 -18 000 0 0 0 0 0 -10M -10000 -40M
commonStockIssued 0 0 -120 000 -218 000 15M 9M 3M 40 000 3M 15M 32M 0
commonStockRepurchased -13 000 0 13 000 0 0 0 -40 000 40 000 0 365 000 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 30 000 -30 000 0 56 000 0 -119 000 19M -40 000 0 -2M 0 138 000
netCashUsedProvidedByFinancingActivities 30 000 -3M -135 000 -180 000 15M 8M 3M 40 000 3M 3M 32M -40M
effectOfForexChangesOnCash 0 0 0 0 0 0 13M -13M 0 0 0 0
netChangeInCash -11M -10M -9M -5M 6M -2M -5M 7M -15M -7M 18M 9M
cashAtEndOfPeriod 21M 32M 42M 49M 54M 48M 51M 56M 49M 64M 71M 53M
cashAtBeginningOfPeriod 32M 42M 51M 54M 48M 51M 56M 49M 64M 71M 53M 43M
operatingCashFlow -11M -8M -9M -5M -9M -11M -8M -3M -8M -10M -14M -16M
capitalExpenditure 16 000 0 0 49 000 -36 000 -13 000 -7000 -281 000 -214 000 -108 000 -22 000 -38 000
freeCashFlow -11M -8M -9M -5M -9M -11M -8M -3M -8M -10M -14M -16M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2022 q2
2022-08-12 ET (fiscal 2022 q2)
2022 q1
2022-05-16 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-08 21:07 ET
Kala Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-08 21:07 ET
Kala Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-08 21:07 ET
Kala Pharmaceuticals published news for 2025 q4
SEC form 8
2025-12-16 18:28 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-16 18:28 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-16 14:32 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-05 16:05 ET
Kala Pharmaceuticals published news for 2025 q3
SEC form 10
2025-11-19 07:26 ET
Kala Pharmaceuticals reported for 2025 q3
SEC form 8
2025-09-29 12:08 ET
Kala Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-29 12:08 ET
Kala Pharmaceuticals published news for 2025 q2
SEC form 10
2025-08-08 12:06 ET
Kala Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-08 12:01 ET
Kala Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-08 12:01 ET
Kala Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-14 20:22 ET
Kala Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Kala Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Kala Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Kala Pharmaceuticals published news for 2025 q1
SEC form 10
2025-03-31 12:03 ET
Kala Pharmaceuticals reported for 2024 q4
SEC form 10
2025-03-31 00:00 ET
Kala Pharmaceuticals reported for 2024 q4
SEC form 8
2025-03-31 00:00 ET
Kala Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-31 00:00 ET
Kala Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-12 16:01 ET
Kala Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-12 08:07 ET
Kala Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-12 08:07 ET
Kala Pharmaceuticals published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Kala Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-06 00:00 ET
Kala Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 00:00 ET
Kala Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 00:00 ET
Kala Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-14 00:00 ET
Kala Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-14 00:00 ET
Kala Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-14 00:00 ET
Kala Pharmaceuticals published news for 2024 q1
SEC form 10
2024-03-29 08:06 ET
Kala Pharmaceuticals reported for 2023 q4
SEC form 8
2024-03-29 08:01 ET
Kala Pharmaceuticals published news for 2023 q4
SEC form 8
2024-03-29 08:01 ET
Kala Pharmaceuticals published news for 2023 q4
SEC form 10
2024-03-29 00:00 ET
Kala Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Kala Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-13 00:00 ET
Kala Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Kala Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-04 00:00 ET
Kala Pharmaceuticals reported for 2023 q2
SEC form 10
2023-05-09 00:00 ET
Kala Pharmaceuticals reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Kala Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-27 08:06 ET
Kala Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-13 16:03 ET
Kala Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-03 08:16 ET
Kala Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-03 08:05 ET
Kala Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-03 00:00 ET
Kala Pharmaceuticals reported for 2022 q4
SEC form 8
2023-03-03 00:00 ET
Kala Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-01 16:33 ET
Kala Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-19 16:14 ET
Kala Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-10 07:05 ET
Kala Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-27 16:13 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-09 16:30 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-28 16:52 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-08 16:01 ET
Kala Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-08 08:05 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Kala Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Kala Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-01 16:11 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-01 16:05 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-20 16:01 ET
Kala Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-09 17:00 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-30 17:00 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-19 07:08 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-11 16:25 ET
Kala Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-11 07:01 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Kala Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Kala Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-12 17:10 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-08 17:00 ET
Kala Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-21 16:15 ET
Kala Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-27 16:30 ET
Kala Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-23 06:01 ET
Kala Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-16 16:22 ET
Kala Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-16 07:01 ET
Kala Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Kala Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Kala Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-29 16:01 ET
Kala Pharmaceuticals published news for 2022 q1
SEC form 10
2022-03-29 16:34 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-29 07:05 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-29 00:00 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-22 16:01 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-04 17:00 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-28 17:25 ET
Kala Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-20 16:05 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-17 20:02 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-17 20:00 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-15 16:19 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-15 08:59 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-19 16:06 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-18 08:05 ET
Kala Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 16:02 ET
Kala Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-05 07:01 ET
Kala Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Kala Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Kala Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 16:01 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 16:02 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 07:04 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 07:00 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 08:00 ET
Kala Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-25 16:01 ET
Kala Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-25 07:01 ET
Kala Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-07 07:02 ET
Kala Pharmaceuticals published news for 2020 q4
SEC form 10
2020-11-05 16:03 ET
Kala Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 07:01 ET
Kala Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-27 07:03 ET
Kala Pharmaceuticals published news for 2020 q3